Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Govt Weighs Additional Copays for OTC-Like Drugs in Economic Package
The Japanese government is considering introducing additional out-of-pocket charges for “OTC-like” prescription medicines as part of the comprehensive economic package due out later this month, Jiho learned on November 18. The concrete system design is expected to be completed in…
To read the full story
Related Article
- LDP Leans Towards “Special Charges” for OTC-Like Drugs, Not Coverage Removal
December 15, 2025
- Panel Backs Extra Charges for OTC-Like Drugs While Keeping Coverage, but Design Details Still Divisive
November 28, 2025
- LDP, Ishin Start Framing Copay Models for OTC-Like Drugs: Bilateral Talks
November 25, 2025
- Japan Finalizes Economic Package Positioning Pharma as “Core Industry”
November 25, 2025
- Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
November 21, 2025
- Ishin Presses Govt to Commit to OTC-Like Drug Reform by FY2026
November 13, 2025
- LDP, Nippon Ishin to Form Coalition; OTC-Like Drug Copay Review Set for FY2025
October 21, 2025
- Japan OKs Honebuto Paper with Softened Phrasing on CEA, Sign of Change to Social Security Budgeting
June 16, 2025
- 3 Parties Agree to Review OTC-Like Drugs from FY2026, but Details Still in the Air
June 9, 2025
REGULATORY
- MFN Now a Factor in Japan’s Drug Pricing Debate: New Pharma Policy Chief
September 11, 2026
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…